The addition of tumor-necrosis factor-α (TNF-α) to this treatment approach has changed the situation dramatically. High response rates and limb-salvage rates have been reported in multicenter ...
z5.keio.jp Objectives To investigate the possible role of baseline plasma tumour necrosis factor alpha levels (baseline-TNF) on the clinical response to infliximab in patients with rheumatoid ...
TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and ...
Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...
They conducted an observational, retrospective study measuring interleukins 1β, 6, 8, 10, and tumor necrosis factor-alpha (TNFα) in the vitreous humor of patients with type 2 diabetes, proliferative ...